PE20010680A1 - Uso de lasofoxifeno - Google Patents

Uso de lasofoxifeno

Info

Publication number
PE20010680A1
PE20010680A1 PE2000001009A PE0010092000A PE20010680A1 PE 20010680 A1 PE20010680 A1 PE 20010680A1 PE 2000001009 A PE2000001009 A PE 2000001009A PE 0010092000 A PE0010092000 A PE 0010092000A PE 20010680 A1 PE20010680 A1 PE 20010680A1
Authority
PE
Peru
Prior art keywords
lasofoxifeno
dose
phenyl
tetrahidronaftalen
lasophoxifene
Prior art date
Application number
PE2000001009A
Other languages
English (en)
Inventor
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010680A1 publication Critical patent/PE20010680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE UN AGONISTA/ANTAGONISTA DEL ESTROGENO TAL COMO LASOFOXIFENO (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL, D-TARTRATO, UTILIZANDO 0,8mg/DOSIS Y 20mg/DOSIS POR UN PERIODO DE TIEMPO QUE OSCILA ENTRE UNA Y CUATRO SEMANAS. EL LASOFOXIFENO ES UTIL PARA EL TRATAMIENTO DE LA OBESIDAD, CANCER DE MAMA, OSTEOPOROSIS, ENDOMETRIOSIS, ENFERMEDADES CARDIOVASCULARES, HIPERCOLESTEROLEMIA
PE2000001009A 1999-09-29 2000-09-26 Uso de lasofoxifeno PE20010680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15665299P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
PE20010680A1 true PE20010680A1 (es) 2001-06-29

Family

ID=22560457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001009A PE20010680A1 (es) 1999-09-29 2000-09-26 Uso de lasofoxifeno

Country Status (20)

Country Link
US (1) US6436977B1 (es)
EP (1) EP1092431B1 (es)
JP (1) JP2001097862A (es)
KR (1) KR100468246B1 (es)
AT (1) ATE339201T1 (es)
AU (1) AU781828B2 (es)
CA (1) CA2321369C (es)
CO (1) CO5200833A1 (es)
CY (1) CY1105235T1 (es)
DE (1) DE60030654T2 (es)
DK (1) DK1092431T3 (es)
ES (1) ES2269071T3 (es)
HU (1) HUP0003836A3 (es)
IL (1) IL138634A (es)
MY (1) MY121519A (es)
NZ (2) NZ516413A (es)
PE (1) PE20010680A1 (es)
PT (1) PT1092431E (es)
TW (1) TWI224001B (es)
ZA (1) ZA200005141B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
WO2003004031A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
SG10201913951YA (en) 2016-10-11 2020-03-30 Univ Duke Lasofoxifene treatment of er+ breast cancer
EP3773524A4 (en) 2018-04-10 2021-12-22 Duke University TREATMENT OF BREAST CANCER WITH LASOFOXIFEN
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (en) 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications

Also Published As

Publication number Publication date
KR20010061927A (ko) 2001-07-07
US6436977B1 (en) 2002-08-20
MY121519A (en) 2006-01-28
DE60030654T2 (de) 2007-04-05
CA2321369A1 (en) 2001-03-29
EP1092431A2 (en) 2001-04-18
HU0003836D0 (en) 2000-12-28
ZA200005141B (en) 2002-03-26
NZ516413A (en) 2004-12-24
PT1092431E (pt) 2006-12-29
NZ507200A (en) 2004-12-24
EP1092431A3 (en) 2002-02-13
DE60030654D1 (de) 2006-10-26
CY1105235T1 (el) 2010-03-03
KR100468246B1 (ko) 2005-01-27
HUP0003836A2 (hu) 2001-10-28
AU781828B2 (en) 2005-06-16
IL138634A (en) 2006-08-01
CO5200833A1 (es) 2002-09-27
AU5661800A (en) 2001-04-05
DK1092431T3 (da) 2006-12-18
IL138634A0 (en) 2001-10-31
CA2321369C (en) 2007-07-17
JP2001097862A (ja) 2001-04-10
ATE339201T1 (de) 2006-10-15
ES2269071T3 (es) 2007-04-01
EP1092431B1 (en) 2006-09-13
TWI224001B (en) 2004-11-21
HUP0003836A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
PE20010680A1 (es) Uso de lasofoxifeno
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
MY122391A (en) Piperazine derivatives as 5-ht1b antagonists
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
IL154988A0 (en) Pharmaceutical compositions containing a 5-ht3 receptor antagonist
ATE345804T1 (de) Estrogenersatztherapie
UA86957C2 (ru) Производные азепиноиндола в качестве фармацевтического средства
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
DE60216233D1 (en) Carbolinderivate
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
BR9909486A (pt) Compostos calcilìticos
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
TW200507857A (en) Combination of an aldosterone receptor antagonist and an anti-obesity agent
TW200508199A (en) Novel compound
SV2002000005A (es) Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv
MXPA03002909A (es) Compuestos quimicos.
TW200503667A (en) Therapeutic combinations
HK1087357A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1- propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder.
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
CL2010001471A1 (es) Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
PE20020466A1 (es) Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama
GB0027705D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC Refusal